Life Science Today

This week, I have an announcement to make. Find out more athttps://LifeScienceTodayPodcast.comAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyoutFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSanofi/TakedaUniQure & CSLFog PharmaMerck + Imago About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvalsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIndivior + OpiantRegeneron + CytomXRezoProventionAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

More CRISPR data, oncology wins, and a new player in ophthalmologyFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIntelliaRegeneronViatris + Oyster PointAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Billion-dollar acquisitions, troubled waters for some biotech's, and a prosperous outlook for othersFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSumitovant + MyovantThermo Fisher + Binding Site GroupAstellas & TayshaAgiosVaxctyeAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future. Find out more athttps://LifeScienceTodayPodcast.comStory References FDAAbbVie + DJSRoche + HookipaKyvernaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

One biotech is on a roll, another is moving quickly, Amazon money for cancer, and some clinical development news Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesDICEOdysseyFred HutchMerck (MSD), Merck Story 2About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Biotech's with a series A, a series C, some debt financing, and there is even a Biopharma heading for a SPACFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesNested TherapeuticsCellarityReplimuneEstrella BiopharmaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Major Alzheimer's news, an ALS approval, and expanded therapies for skin conditionsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesEisai + BiogenAmylyxSanofi + RegeneronAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

A $900 raise, gene therapy news, a quick IPO, and merge three for $100MFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlnylam, Link 2, Link 3Intellia TherapeuticsThird Harmonic BioGalvanize TherapeuticsAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

A critical aesthetics approval, site network buy-up, a very normal oncology biotech, and a busy week for one company. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesRevanceVelocity + MedPharmicsArsenalSpringWorks Link 1, Link 2, Link 3About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

A $1.1B acquisition, two FDA approvals, and grants for mRNA vaccines. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesNovo + FormaSanofiBoehringer IngelheimArcturusAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlcon + AerieNovartis + SandozLabcorp + RWJBHAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Gene therapy approval, opioid costs continue, a $650M deal, and a $3.5B RNA partnership. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesBluebirdEndo & PharmaciesGenentech + JemincareMerck + OrnaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Spending that COVID money, brain money, Irish money, and another oncology approval. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizerCerevelAbbottAstraZeneca + Daiichi SankyoAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

This week, we take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What happens when companies fail, people lie, and good drugs make bad lives? Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesZymergen + GinkgoCassavaTeva About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

There's a SPAC, expanded FDA approval, more of the common, and two Bs, two AsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesZyVersaIncyteRevolutionFronteraCAMP4ForSightAuronAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Cell therapy acquisition, royalties sold, biobucks-like deal, successful raise, and Chinese Venture Capital Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesVertex + ViaCyteTheravance BiopharmaMerck + OrionPliant Therapeutics QimingAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

FEED DROP - Clinical Research Evolved Noah and John talk with Dan Agroskin, a managing director at a leading private equity firm with a focus on the clinical research industry. We discuss how investments shape industries, what entrepreneurs should think about private equity, and the forces that drive exceptional business growth.Find Out MoreDan AgroskinClinical Research EvolvedNoah Goodson, PhDJohn ReitesKyle RickettsAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Double acquisition, private money, affordable deals, and a surprising $70M launchFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGalapagos + CellPoint + AboundBioRadiusIpsen + EpizymeDEM Bio About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Crohn's approval, new VC round, direct offerings, and potential asset sales. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAbbVieThird RockScholar RockKyowa Kirin About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Gene therapy, minor legislation, a $625M series D, and four companies raise $373M.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesBlueBirdFDAResilienceCorvia, Code, Mineralys, Tessa About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Pharma buys, pharma splits, pharma trades, and oncology biobucks from pharmaFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGSK + AffinivaxPfizer – HaleonRegeneronRoche + RepareAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Pox progress, an oncology acquisition, and we look at $360M worth of biotech fundingFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesChimerix, Emergent, SIGA Merck & KelunInceptor, Laekna, KriyaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

An $11.6B yes, $11.7B delay, drop the A1C with GLP, and a billion bio-bucksFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizer + BiohavenRegulatorsLillyBridgeBio + BMSAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Resets for biotech, antibiotics approval not enough, continued consolidation, and a normal dealFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesZymeworksPhathomCatalystCenExelIntercept + AdvanzAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Pharma Q1 reports are rolling in, COVID boost turned sustainable, and weight loss battle loomsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesMerckSanofiJ&JThermoFisherNovo NordiskEli LillyAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Drops for reading, a $220M raise, and an acquisition straight out of the moviesFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesOrasisReifyBlackrock + MindXAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesFDAAntares + HalozymeGSK + SierraAnsa BiotechnologiesAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Viral therapies, rare disease approvals, and lab space premiumsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizer + ReViralNovartisCharles River + Explora LabsAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Big compensation, mild mergers, a Kite in an updraft, and tightening the biotech beltFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGinkgoEagle + AcaciaGileadTaysha/Orchard/SilverbackAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

$2 billion in capital raises mostly by companies that start with the letter A. Find out more athttps://LifeScienceTodayPodcast.comStory References2seventy BioAscendisApellisArgenxAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Case closed on patents, Alzheimer's data, generic approvals, and expanded approvals.  Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlexion + ChugaiBiogenViatrisAbbVieAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Technology for inclusion, layoffs, oncology approvals, and $200M for a tech platform. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesGileadAstraZeneca + Merck + MyriadDNAnexus About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Who owns CRISPR, a collaboration, the classics, and more money for biotech.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesSanofi + AdageneAbbVie + SyndesiAtlasAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

CRISPR works, the opioid epidemic makes amends (sort of), and the SPAC that wasn'tFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIntelliaPurdue PharmaAmicus SPACAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

The PD1 that lost, biopharma earns FDA approval, and the Biotech market is cool not dead Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesEli Lilly + Innovent BiologicsAgiosTC BiopharmBlue Water VaccinesMeihua About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Dragons over unicorns, to CRISPR and beyond, spin-out-and-sell, and expanded approvals.  Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesArcellxIntellia + RewriteNavitor + JanssenViiV About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Bispecific antibodies, ocular oncology, Biogen sells, Lilly Builds, and the treatment of a lifetimeFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGenentechImmunocoreBiogenEli LillyTenSixteenAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Psychedelic SPACs, eczema frenzy, bio-outs without the biobucks, back on track, and the mega-deal that wasn't Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesEleusisAbbvie/Pfizer/LeoUCB + ZogenixKuraGSK - UnileverAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Oncology partners, Parkinson's partners, expanded European Commission, expanded FDA, and bacterial vaccinesFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesScorpion & AstraZeneca ABL & SanofiVertexCochlearVaxcyteAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Devices with tech enablement, nano particles, Chinese approvals, and a massive series B for  biotechnologyFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesStryker + VoceraMerck KGaA + ExeleadBeiGeneEikonAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

We've got a new name, gene therapy buyout, a lion of an approval, and an inescapable spotlight. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesNovartis + GyroscopeLeoBiogenBiogen 2About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Acquiring the acquired, EHR acquisition, first approvals, and a new fund for the new yearOriginally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesCSL + ViforOracle + CernerCalliditasOmegaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Antitrust AI, development AI, expanded approval, mega seeds, and biosimilar SPACsOriginally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesMicrosoft + NuanceRoche + RecursionHeron1EAlvotech About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Double acquisitions in Switzerland, FDA holds and what that means, CMV therapy, rare + oncology continues, BioCryst draws millions, and deer. Originally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesVifor + Sanifit + InositecKuraDifferential SyndromeTakedaAadiBioCrystUSDAAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Top dollar lab notes, lab consolidation, RNA sells, and two new approval areasOriginally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesBenchlingLabcorpNovo NordiskBioMarinBioMarin 2AppliedVRAppliedVR 2Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodsonAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

A giant breaks in two, acquisitions in women's health, Medicare cost, rare approvals, more CRISPR, and a legacyOriginally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesJohnson & JohnsonOrganonMedicarePharmaEssentiaArbor BiotechnologiesGlen de VriesAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Roche and Novartis part ways, Alphabet likes AI, Pfizer 89%, Series A, B, and the money that gets you thereOriginally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesRoche - NovartisAlphabetPfizerParthenonAntiosMission BioSection 32About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

This week, we have a special bonus interview with Danielle Coe, founder of Black Women in Clinical Research. Danielle CoeBlack Women in Clinical ResearchOriginally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comBackgroundDanielle Coe started her career as a lab-based scientist, after learning from a friend about work in clinical research she pivoted her goals. It wasn't immediate, but she eventually found her way into the industry and has forged a path on the site side clinical research. Through the process she was struck by the lack of women of color. To help decrease this gap and drive diversity through peer-to-peer support, Danielle created Black Women in Clinical Research. The goal? To help other black women start and build careers in clinical research through community support, resume crafting, interview preparation, negation tactics for salary, and more.  Danielle carved time out of her busy schedule to share her story. I really appreciate the way she has turned the challenges she faced into a solution for others and her drive to provide practical solutions, not just nice ideas. About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

Unique therapies including anti-opioid overdose, ocular implants, fish skin, UV light, digital therapeutics, and the impact of approvalsOriginally Published as The Niche Podcast.Find out more athttps://LifeScienceTodayPodcast.comStory Referenceshttps://tinyurl.com/Niche-074-1https://tinyurl.com/Niche-074-2https://tinyurl.com/Niche-074-3https://tinyurl.com/Niche-074-4https://tinyurl.com/Niche-074-5https://tinyurl.com/Niche-074-6https://tinyurl.com/Niche-074-7https://tinyurl.com/Niche-074-8About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.